CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients with Cancer o

  
    
  
  
    
      Canopus BioPharma, Inc. (OTC: CBIA), is pleased to announce that the 
      South African Medicines Control Council has granted approval for a Phase 
      II study in 30 cancer patients evaluating the protective effect of 
      CB1400 on the gastrointestinal tract from radiation-induced mucositis. 
      This new trial is an important step forward in the development of CB1400 
      as a novel, preventative, anti-mucositis agent.
    
    
      Oral and gastrointestinal (GI) mucositis is a painful, debilitating, and 
      sometimes fatal side-effect of radiation therapy and cancer 
      chemotherapy. No preventative mucositis medicines are available, and few 
      treatments are effective. With some cancer therapies, oral mucositis can 
      develop in over 90% of patients. Consequently, it is a widespread 
      problem with considerable economic and healthcare implications. There is 
      a real need for an effective and well-tolerated mucositis prophylactic. 
      The United States market for a preventative mucositis agent is estimated 
      to be over $1 billion per annum.
    
    
      In work carried out on behalf of Canopus, CB1400 has already been shown 
      to have protective and antimutagenic effects when tested in an animal 
      model of mucositis. Complete protection of the GI tract was seen in 
      gamma-radiated mice pre-treated with oral CB1400 (100mg/kg/day). Even 
      with high doses of radiation (10Gy), there was no evidence of mucositis: 
      weight gain was observed in the CB1400 pre-treated groups; all mice 
      treated with placebo died.
    
    
      Canopus has applied to undertake further clinical studies with leading 
      oncologists in Australia, South Africa and the U.S., investigating 
      CB1400 as a preventative mucositis agent in head and neck cancer 
      patients who are receiving radiation and/or chemotherapy.
    
    
      About Canopus BioPharma, Inc.:
    
    
      Canopus BioPharma, Inc. (OTC: CBIA) is dedicated to providing the 
      safest, most cost effective and efficacious pharmaceutical products and 
      assay methods in the areas of infectious disease, radiation protection, 
      cancer, and addiction. With innovative science, proven research and 
      development leadership, and superior products and compounds, Canopus 
      BioPharma has, since 2001, been committed to becoming a market trend 
      setter in a new era of healthcare. In addition, the Company is a world 
      leader in the development of novel camelid antibody products to provide 
      unique avenues of progress and improvement in assay methods and 
      monitoring capabilities for physicians, patients and researchers, 
      particularly for food chain protection applications. Canopus maintains 
      staff in Australia, South Africa, Ireland, Panama and the USA. 
      Additional information on the Company is available at www.canopusbiopharma.com.